Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata listed "BIOLIFE SOLUTIONS INC" but filing text confirms "CRYOMEDICAL SCIENCES, INC.")
Reporting Period: Three months ended September 30, 1996 (Unaudited)
Business Overview: The Company researches, develops, manufactures, and markets cryosurgical systems, primarily the AccuProbe System, for use in dermatology, surgery, and urology. The Company is transitioning to a 52-week fiscal year ending December 29, 1996.
Key Financial Metrics
| Metric | Q3 1996 | Q3 1995 |
|---|---|---|
| Revenue | $954,106 | $2,019,422 |
| Gross Profit | $482,319 (51% margin) | $1,111,900 (55% margin) |
| Operating Loss | $(351,990) | $(374,505) |
| Net Loss | $(349,715) | $(372,727) |
| Cash & Equivalents (End of Period) | $2,533,808 | $1,083,696 |
| Working Capital | $4,056,456 | $2,533,029 |
| Net Cash Used in Operations | $(586,587) | $(29,150) |
| Net Cash Provided by Financing | $1,974,963 | $20,192 |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 53% year-over-year, dropping from $2.02M to $954K. This was driven by a reduction in AccuProbe system sales (one unit sold vs. six in the prior year) and fewer procedures performed due to lack of Medicare reimbursement for urologic cryosurgery.
- Expense Reductions: Operating expenses decreased significantly, offsetting the revenue drop and narrowing the net loss.
- Research & Development: Decreased 28% to $259K due to staffing reductions and lower grant funding.
- Sales & Marketing: Decreased 57% to $275K due to reduced staffing and marketing activity.
- General & Administrative: Decreased 39% to $301K due to staffing and professional fee reductions.
- Liquidity Improvement: Cash and working capital increased substantially due to a $1.96M financing transaction involving Series D convertible preferred stock. The majority of proceeds were received in late September, with the transaction closing October 2, 1996.
Outlook, Risks, and Management Commentary
- Reimbursement Risk: On October 17, 1996, the Company was advised that the Health Care Financing Administration (HCFA) planned to adopt a national non-coverage policy for cryoablation of the prostate. This continues Medicare's non-reimbursement stance, which constrains sales and utilization of the AccuProbe system.
- Market Position: The American Urological Association (AUA) has reclassified cryosurgery in urology from "experimental" to a recognized management method for prostate adenocarcinoma, though reimbursement remains a barrier.
- Capital Strategy: Management expects current cash and working capital to fund operations for the next 12 months, contingent on sales levels. The Company plans to continue cost reductions and may pursue additional short-term or equity financing if necessary.
- Capital Expenditures: CapEx for the quarter was $105K. The Company does not expect to spend more than $200K on additional equipment for the remainder of the transition period.
Investor Verification Checklist
- Financing Terms: Verify the conversion formula and timeline for the $1.96M Series D Preferred Stock issued to foreign investors (conversion begins 40 days post-closing).
- Reimbursement Policy: Confirm the final status of the HCFA non-coverage policy for urological cryosurgery and its impact on future sales projections.
- Revenue Mix: Assess the sustainability of revenue given the shift from system sales to rentals and accessories, and the reliance on non-Medicare payers.
- Cash Burn Rate: Monitor the net cash used in operating activities ($587K for the quarter) against the current cash balance to validate the 12-month runway estimate.